Skip to main content
Intermediate Technical IVT

platinum-resistant

Cancer that progresses during or within six months of completing platinum-based chemotherapy treatment.

Full Definition

Platinum-resistant ovarian cancer is defined as disease that progresses during platinum-based treatment or recurs within six months of completing a platinum-containing regimen. This classification is crucial for treatment planning as platinum-resistant cancers show poor response rates to additional platinum therapy and require alternative treatment approaches. The distinction is made based on the platinum-free interval, with resistance indicating a more aggressive disease biology and generally poorer prognosis. Treatment options for platinum-resistant disease include non-platinum chemotherapy agents, targeted therapies, and clinical trials.

Usage

Usage note: Hyphenate as platinum-resistant; six-month cutoff distinguishes from platinum-sensitive (>6 months).

In Context

  • "The patient's disease recurred four months after carboplatin completion, classifying it as platinum-resistant." — Oncology assessment
  • "Given the platinum-resistant status, treatment was changed to pegylated liposomal doxorubicin." — Treatment modification note

Also known as

platinum-refractory

Contrasted with

platinum-sensitive

Don't confuse with

platinum-sensitive platinum-free interval

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON